Wilkins Investment Counsel Inc. Buys 47,172 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Wilkins Investment Counsel Inc. grew its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 630.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 54,657 shares of the medical research company's stock after purchasing an additional 47,172 shares during the period. IQVIA comprises 1.6% of Wilkins Investment Counsel Inc.'s portfolio, making the stock its 28th largest holding. Wilkins Investment Counsel Inc.'s holdings in IQVIA were worth $10,741,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Avior Wealth Management LLC raised its stake in shares of IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company's stock worth $38,000 after purchasing an additional 87 shares in the last quarter. Synergy Asset Management LLC acquired a new position in IQVIA in the fourth quarter worth approximately $33,000. Meeder Asset Management Inc. raised its position in IQVIA by 353.7% during the third quarter. Meeder Asset Management Inc. now owns 245 shares of the medical research company's stock valued at $58,000 after acquiring an additional 191 shares in the last quarter. Versant Capital Management Inc lifted its stake in IQVIA by 46.0% in the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company's stock valued at $58,000 after acquiring an additional 93 shares during the last quarter. Finally, SBI Securities Co. Ltd. bought a new stake in IQVIA in the fourth quarter worth approximately $60,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

IQVIA Stock Performance

IQV traded up $0.46 on Monday, hitting $186.35. 1,477,630 shares of the stock traded hands, compared to its average volume of 1,240,830. The business has a fifty day moving average price of $194.58 and a two-hundred day moving average price of $207.73. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 52 week low of $179.28 and a 52 week high of $254.54. The firm has a market capitalization of $32.86 billion, a PE ratio of 24.85, a P/E/G ratio of 1.99 and a beta of 1.50.

IQVIA (NYSE:IQV - Get Free Report) last issued its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

IQV has been the subject of several analyst reports. JPMorgan Chase & Co. reduced their price objective on shares of IQVIA from $240.00 to $232.00 and set an "overweight" rating for the company in a research note on Tuesday, February 18th. Robert W. Baird reduced their price target on IQVIA from $212.00 to $210.00 and set a "neutral" rating for the company in a research report on Tuesday, January 21st. StockNews.com lowered IQVIA from a "buy" rating to a "hold" rating in a report on Wednesday, March 12th. BTIG Research lowered IQVIA from a "buy" rating to a "neutral" rating in a report on Monday, February 3rd. Finally, Stifel Nicolaus lowered their price target on IQVIA from $273.00 to $261.00 and set a "buy" rating on the stock in a report on Friday, February 7th. Five analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $249.05.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.